Latest Research And Development News

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

Papyrus Australia has made significant strides in Q2 2025, launching its Rapid Prototyping and R&D Facility and successfully trialling new banana fibre-based products, while deepening academic partnerships.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

State Gas Limited has successfully drilled two new wells at its Rolleston West Project, intersecting significant coal seams and initiating production testing, while engaging NSAI for independent reserve certification.

Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Marquee Resources has progressed its Mt Clement antimony-gold project with Phase 1 drilling completed and assay results pending, alongside a $596,000 capital raise and a key executive appointment.

Cadoux Limited has made significant progress in developing its high purity alumina and rare earths projects, advancing engineering design, customer engagement, and funding strategies during the June 2025 quarter.

Audio Pixels Holdings reports a delay in its MEMS wafer production due to a key fabrication step requiring revision, while its shares remain suspended on the ASX. The company signals the need for additional funding within six months to sustain its R&D efforts.

Red Metal Limited’s June 2025 Quarterly Report highlights significant metallurgical advances at its Sybella rare earth project and accelerated drilling programs across copper-gold and gold targets, supported by government grants and resource upgrades.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.